Tryngolza Injection, Solution
Product Images NDC 71860-102

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Tryngolza (NDC 71860-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ionis Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Tryngolza 01)

Chemical structure diagram of olezarsen sodium, showing the detailed molecular arrangement including phosphate groups, sugar rings, and base pairs, with R groups identified as OCH2CH2OCH3.*

FDA Label Image

Figure 2 (Tryngolza 02)

A line graph depicting median percent change in fasting triglycerides (mg/dL) over a 12-month period, comparing TRYNGOLZA 80 mg and placebo groups. The x-axis shows visits from Baseline to Month 12, and the y-axis measures percent change. TRYNGOLZA 80 mg demonstrates a significant decrease from Month 1 onward, while placebo shows minimal change.*

FDA Label Image

Figure 3 (Tryngolza 03)

A line graph comparing the median fasting triglycerides levels (mg/dL) over 12 months between TRYNGOLZA 80 mg subcutaneous injection and placebo groups. The x-axis shows time points from baseline to month 12, while the y-axis represents triglyceride levels. TRYNGOLZA 80 mg shows a general decrease and stabilization over time compared to the placebo group.*

FDA Label Image

Figure 4 (Tryngolza 04)

TRYNGOLZA 50 mg/.8 mL subcutaneous injection solution vial label featuring olezarsen sodium. The label is primarily light gray with an orange cap on the vial. There is a small window on the label showing part of the vial contents and measuring scale. Manufactured by Ionis Pharmaceuticals, Inc.*

FDA Label Image

Figure 5 (Tryngolza 05)

An instructional diagram showing parts of a prefilled syringe for subcutaneous injection. It labels the plunger, viewing window with medicine inside, clear cap, and an orange needle shield at the tip.*

FDA Label Image

Figure 6 (Tryngolza 06)

FDA Label Image

Figure 7 (Tryngolza 07)

Illustration of a red sharps disposal container with an open white lid, used for the safe disposal of needles and other sharp medical instruments.*

FDA Label Image

Figure 8 (Tryngolza 08)

FDA Label Image

Figure 9 (Tryngolza 09)

TRYNGOLZA 50 mg/0.8 mL subcutaneous injection by Ionis Pharmaceuticals, Inc. The image displays a single-dose prefilled syringe with the medication solution inside, designed for subcutaneous administration. The syringe barrel is clear with measurement markings.*

FDA Label Image

Figure 10 (Tryngolza 10)

An instructional illustration showing the process of refrigerating a medication carton and then waiting for 30 minutes after removal, indicated by a clock icon and the text 'Wait 30 minutes.' This suggests allowing the medication to reach room temperature before use.*

FDA Label Image

Figure 11 (Tryngolza 11)

An illustration of a device resembling a test strip or injection check with a small viewing window labeled 'Check' on one end and an expiration date field labeled 'EXP. MM/YYYY' on the other end. No product name or strength is visible.*

FDA Label Image

Figure 12 (Tryngolza 12)

An instructional diagram showing subcutaneous injection sites for TRYNGOLZA (olezarsen sodium) injection, solution. The left side illustrates injection areas for all users including the stomach and front of the thighs. The right side shows injection sites for healthcare providers or caregivers only, located on the back of the upper arms.*

FDA Label Image

Figure 13 (Tryngolza 13)

An instructional illustration showing two steps of hand hygiene: the left side depicts hands being washed with water and soap, while the right side shows a hand drying or wiping on a towel or cloth. This likely demonstrates proper hand cleaning technique prior to subcutaneous injection.*

FDA Label Image

Figure 14 (Tryngolza 14)

Illustration showing hands holding a syringe labeled with an orange needle shield and a clear cap. The image depicts the removal of the clear cap from the syringe, with a green arrow indicating the direction to pull the cap away.*

FDA Label Image

Figure 15 (Tryngolza 15)

Instructional illustration showing three steps for using a prefilled injector pen: a) Place the pen vertically at a 90-degree angle; b) Push down until a click is heard; c) Hold the pen in place for 10 seconds. The image visually guides subcutaneous injection technique, likely for TRYNGOLZA injection solution.*

FDA Label Image

Figure 16 (Tryngolza 16)

An instructional illustration showing two hands administering an injection using a syringe with an orange plunger rod. The left side depicts pushing the plunger down to deliver the injection, while the right side shows pulling the syringe up after injection is complete. Directions are indicated with green arrows.*

FDA Label Image

Figure 17 (Tryngolza 17)

An instructional illustration showing a hand holding a syringe with an orange label, positioned above a red sharps disposal container, indicating the proper disposal method for a used injection device.*

FDA Label Image

Figure 18 (Tryngolza 18)

TRYNGOLZA 80 mg/0.8 mL (olezarsen injection) single-dose autoinjector carton label for subcutaneous use. The label states each autoinjector contains 80 mg olezarsen (equivalent to 84 mg olezarsen sodium) in 0.8 mL solution, indicated for familial chylomicronemia syndrome treatment. Includes labeler Ionis Pharmaceuticals, Inc., NDC 71860-101-01, and provides spaces for GTIN, expiration date, and lot number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.